Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2578770rdf:typepubmed:Citationlld:pubmed
pubmed-article:2578770lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:2578770lifeskim:mentionsumls-concept:C0278996lld:lifeskim
pubmed-article:2578770lifeskim:mentionsumls-concept:C0008838lld:lifeskim
pubmed-article:2578770lifeskim:mentionsumls-concept:C0025677lld:lifeskim
pubmed-article:2578770lifeskim:mentionsumls-concept:C0135981lld:lifeskim
pubmed-article:2578770lifeskim:mentionsumls-concept:C0549178lld:lifeskim
pubmed-article:2578770lifeskim:mentionsumls-concept:C0576773lld:lifeskim
pubmed-article:2578770lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:2578770pubmed:issue2lld:pubmed
pubmed-article:2578770pubmed:dateCreated1985-3-20lld:pubmed
pubmed-article:2578770pubmed:abstractTextTwenty-one patients with advanced or recurrent squamous cell carcinoma of the head and neck were treated with cisplatin, methotrexate and continuous subcutaneous infusion of peplomycin. The overall response rate was 62% (13/21) with 19% (4/21) complete response. The median duration of partial response was 2 months, while that of complete response was 3 months. Toxic effects were acceptable with no fatalities, but nephrotoxicity (33%), leukocytopenia (24%), thrombocytopenia (29%) and severe nausea and vomiting (76%) occurred. Pulmonary toxicity due to continuous subcutaneous infusion of peplomycin (15 mg/day, 4 days) was not seen.lld:pubmed
pubmed-article:2578770pubmed:languagejpnlld:pubmed
pubmed-article:2578770pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2578770pubmed:citationSubsetIMlld:pubmed
pubmed-article:2578770pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2578770pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2578770pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2578770pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2578770pubmed:statusMEDLINElld:pubmed
pubmed-article:2578770pubmed:monthFeblld:pubmed
pubmed-article:2578770pubmed:issn0385-0684lld:pubmed
pubmed-article:2578770pubmed:authorpubmed-author:SakuraiTTlld:pubmed
pubmed-article:2578770pubmed:authorpubmed-author:MurakamiYYlld:pubmed
pubmed-article:2578770pubmed:authorpubmed-author:DoiYYlld:pubmed
pubmed-article:2578770pubmed:authorpubmed-author:AsanoKKlld:pubmed
pubmed-article:2578770pubmed:authorpubmed-author:NishioMMlld:pubmed
pubmed-article:2578770pubmed:authorpubmed-author:SaitohAAlld:pubmed
pubmed-article:2578770pubmed:authorpubmed-author:KagamiYYlld:pubmed
pubmed-article:2578770pubmed:authorpubmed-author:NarimatsuNNlld:pubmed
pubmed-article:2578770pubmed:issnTypePrintlld:pubmed
pubmed-article:2578770pubmed:volume12lld:pubmed
pubmed-article:2578770pubmed:ownerNLMlld:pubmed
pubmed-article:2578770pubmed:authorsCompleteYlld:pubmed
pubmed-article:2578770pubmed:pagination337-42lld:pubmed
pubmed-article:2578770pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2578770pubmed:meshHeadingpubmed-meshheading:2578770-...lld:pubmed
pubmed-article:2578770pubmed:meshHeadingpubmed-meshheading:2578770-...lld:pubmed
pubmed-article:2578770pubmed:meshHeadingpubmed-meshheading:2578770-...lld:pubmed
pubmed-article:2578770pubmed:meshHeadingpubmed-meshheading:2578770-...lld:pubmed
pubmed-article:2578770pubmed:meshHeadingpubmed-meshheading:2578770-...lld:pubmed
pubmed-article:2578770pubmed:meshHeadingpubmed-meshheading:2578770-...lld:pubmed
pubmed-article:2578770pubmed:meshHeadingpubmed-meshheading:2578770-...lld:pubmed
pubmed-article:2578770pubmed:meshHeadingpubmed-meshheading:2578770-...lld:pubmed
pubmed-article:2578770pubmed:meshHeadingpubmed-meshheading:2578770-...lld:pubmed
pubmed-article:2578770pubmed:meshHeadingpubmed-meshheading:2578770-...lld:pubmed
pubmed-article:2578770pubmed:meshHeadingpubmed-meshheading:2578770-...lld:pubmed
pubmed-article:2578770pubmed:meshHeadingpubmed-meshheading:2578770-...lld:pubmed
pubmed-article:2578770pubmed:meshHeadingpubmed-meshheading:2578770-...lld:pubmed
pubmed-article:2578770pubmed:year1985lld:pubmed
pubmed-article:2578770pubmed:articleTitle[Combined chemotherapy for head and neck cancer using cisplatin, methotrexate and continuous subcutaneous infusion of peplomycin].lld:pubmed
pubmed-article:2578770pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2578770pubmed:publicationTypeEnglish Abstractlld:pubmed